Compare GE Vernova Inc (GEV) vs Moderna, Inc. (MRNA) Price & Performance

GE Vernova (GEV) trades at $1,042.98, up 5.26% over 24 hours, reflecting strong momentum near its pivot point of $1,017. The stock exhibits bullish technical signals with moving averages supporting the uptrend. Fundamentally, the company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $17.44 significantly exceeding expectations, though Q2 2026 saw a miss. Revenue growth is solid, projected to rise from $38.07B in 2025 to $41.4B in 2026, while net income margin expanded to 23.04%. The company benefits from a massive $176 billion backlog, positioning it to capitalize on AI-driven power demand.

Outlook remains positive given GEV's strategic role in addressing AI infrastructure bottlenecks, but high valuations (P/E 29.01, EV/EBITDA 86.33) pose risks if execution falters. Analyst consensus is strongly bullish with a $1,270 price target, though investors should monitor quarterly execution against lofty expectations and competitive pressures in the energy sector.

Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.

The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.